MCM Complex Disruption for Selective Cancer Cell Apoptosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in selectively inhibiting cancer cell proliferation without causing significant damage to normal cells, due to the toxicity and lack of specificity of existing anticancer drugs.
Innovation Solution
The method involves disrupting the formation of the functional MCM complex by targeting its subunits, specifically using compounds like 17beta-Deacetyltanghinin that impair the formation of the heterohexameric ring structure, preventing its nuclear localization and thereby inhibiting DNA replication and inducing apoptosis in cancer cells while sparing normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cytotoxic compounds are used to inhibit cell proliferation, then anticancer activity is improved, but toxicity to normal cells increases
Solution Approach 1:
The patent applies local quality by making the MCM complex the specific target of the therapeutic action. The compound 17beta-Deacetyltanghinin selectively disrupts MCM complex formation and function, creating a localized effect on DNA replication machinery in cancer cells while leaving normal cells with intact checkpoints unaffected. This targeted approach to the replication licensing mechanism resolves the contradiction by concentrating the anticancer effect specifically where needed.
Solution Approach 2:
The MCM complex serves as an intermediary target between the administered compound and the ultimate effect of cell death. The compound 17beta-Deacetyltanghinin does not directly kill cells but rather disrupts MCM complex assembly and function, which then prevents DNA replication and triggers apoptosis in cancer cells. This intermediary mechanism allows for selective toxicity based on the presence or absence of functional checkpoints.
2Reliability
If compounds that inhibit cell proliferation are developed, then anticancer efficacy is improved, but therapeutic index decreases
Solution Approach 1:
The invention achieves high therapeutic index by applying local quality to the mechanism of action. The MCM complex disruption is the localized target that differentiates cancer cells from normal cells. Since normal cells possess functional checkpoints that can sense and respond to MCM disruption by arresting in G1 phase, while cancer cells lack this checkpoint control and proceed to abortive S phase, the same compound produces different outcomes in different cell types, thereby improving the therapeutic index.
Solution Approach 2:
The patent exploits parameter changes in cell checkpoint functionality between normal and cancer cells. The presence or absence of functional G1/S checkpoints creates a critical parameter difference that determines cell fate after MCM disruption. This parameter change approach allows the same compound to be tolerated by normal cells while being lethal to cancer cells, thus improving therapeutic index while maintaining anticancer efficacy.
3Reliability
If MCM complex formation is disrupted, then DNA replication is inhibited in cancer cells, but specificity towards cancer cells must be achieved
Solution Approach 1:
The patent achieves specificity by applying local quality to the checkpoint control mechanism. While the MCM complex is present in both normal and cancer cells, the functional difference lies in the checkpoint control system. Normal cells have functional checkpoints that can detect MCM disruption and arrest the cell cycle, whereas cancer cells have defective checkpoints that cannot respond appropriately. This local quality difference in checkpoint functionality enables selective killing of cancer cells upon MCM disruption.
Solution Approach 2:
The invention exploits the self-service principle by allowing normal cells to use their own intact checkpoint controls to protect themselves from MCM disruption. When exposed to the compound, normal cells automatically activate their checkpoint mechanisms to arrest in G1 phase, effectively self-protecting without external intervention. Cancer cells, lacking this self-service checkpoint function, cannot protect themselves and proceed to cell death.
Data Source
AI summary
A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds.